|
EMA Taking Comments on Revisions to Biosimilars Guideline
The European Medicines Agency (EMA) wants to update its guideline on biosimilar drugs to reflect the growing complexity of biosimilar products and unique issues concerning their development, an EMA concept paper states.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives